×

Themes

Psoriasis

A case of Netherton's syndrome diagnosed in two adult male siblings
A case of Netherton's syndrome diagnosed in two adult male siblings
Akshay Flora, Cathy Zhao, Annika Smith
Pediatric psoriasis and association with cardiovascular and metabolic comorbidities: systematic review and meta-analysis
Pediatric psoriasis and association with cardiovascular and metabolic comorbidities: systematic review and meta-analysis
Kevin Phan, Geoffrey Lee, Gayle Fischer
Association between psoriasis and diabetes mellitus: A hospital based study of central Nepal.
Association between psoriasis and diabetes mellitus: A hospital based study of central Nepal.
Rabindra Baskota, Anupama Karki, Bhaskar Kayastha
Management of psoriasis in an ageing population: treatment trends and outcomes in age based cohorts
Management of psoriasis in an ageing population: treatment trends and outcomes in age based cohorts
Holly Sexton, Con Dolianitis
Analysis of treatment modalities and risk of adverse events associated with biologic therapy: A 10-year observational review of the Australasian Psoriasis Registry
Analysis of treatment modalities and risk of adverse events associated with biologic therapy: A 10-year observational review of the Australasian Psoriasis Registry
Brent Doolan, Digsu Koye, Con Dolianitis
Efficacy and Safety of Tildrakizumab in Australian Patients with Chronic Plaque Psoriasis in a Phase 3 Clinical Trial
Efficacy and Safety of Tildrakizumab in Australian Patients with Chronic Plaque Psoriasis in a Phase 3 Clinical Trial
Peter Foley, Lynda Spelman, Pablo Fernández-Peñas, Michael Freeman, Rod Sinclair
A Bibliometric Analysis of the Top 100 Cited Articles on Psoriasis
A Bibliometric Analysis of the Top 100 Cited Articles on Psoriasis
Jinni Zhu, Kevin Phan, On Bon Chan, Lena Ly, Antoinette Ciconte
Systematic Review and Meta-Analysis on the Use of Narrowband Ultraviolet B (NBUVB) in Children with Psoriasis
Systematic Review and Meta-Analysis on the Use of Narrowband Ultraviolet B (NBUVB) in Children with Psoriasis
Emma Kim, Gayle Fischer, Geoff Lee
Prevalence of Psoriasis in Multiple Sclerosis in Australian Adult Population
Prevalence of Psoriasis in Multiple Sclerosis in Australian Adult Population
Varitsara Mangkorntongsakul, Olivia Charlton, Kevin Phan, John Parratt, Saxon D Smith
Characterization of Super Responders to Guselkumab Treatment in Moderate-to-Severe Psoriasis: Results from the VOYAGE 1 and 2 Clinical Trials
Characterization of Super Responders to Guselkumab Treatment in Moderate-to-Severe Psoriasis: Results from the VOYAGE 1 and 2 Clinical Trials
Kristian  Reich, Kenneth  B Gordon, Bruce Strober, Richard  G Langley, Michael  Song
Consistent Responses to Guselkumab by Disease Region at Week 48 in the Treatment of Moderate-to-Severe Psoriasis: ECLIPSE Trial Results
Consistent Responses to Guselkumab by Disease Region at Week 48 in the Treatment of Moderate-to-Severe Psoriasis: ECLIPSE Trial Results
Richard  G Langley, Laura Ferris, Kurt Gebauer, Petr Arenberger, Melinda  Gooderham
Pregnancy Outcomes in Women Exposed to Guselkumab: Experience From the Clinical Development Program
Pregnancy Outcomes in Women Exposed to Guselkumab: Experience From the Clinical Development Program
Laura Ferris, April  Armstrong, Tsen-Fang  Tsai, Michael  Song, Paraneedharan Ramachandran
Malignancy Rates and Comparisons to the General US Population Through 3 Years in Guselkumab-treated Moderate-to-Severe Psoriasis Patients in VOYAGE 1&2
Malignancy Rates and Comparisons to the General US Population Through 3 Years in Guselkumab-treated Moderate-to-Severe Psoriasis Patients in VOYAGE 1&2
Kim Papp, Kristian Reich, Ken B Gordon, Mark  Lebwohl, Michael  Song
Dermatology and Rheumatology working together - Psoriatic Disease and beyond
Dermatology and Rheumatology working together - Psoriatic Disease and beyond
Annika Smith, Richard Holland
Improvement in Absolute Psoriasis Area and Severity Index Score Through 3 Years of Continuous Treatment with Guselkumab in VOYAGE 1
Improvement in Absolute Psoriasis Area and Severity Index Score Through 3 Years of Continuous Treatment with Guselkumab in VOYAGE 1
Luis Puig, Kenneth B Gordon, Tsen-Fang  Tsai, Diamant  Thaci, Melinda Gooderham
Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: 3-Year Data from the Phase 3 reSURFACE 1 Study
Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: 3-Year Data from the Phase 3 reSURFACE 1 Study
Mark G Lebwohl, Nehal N Mehta, Alice B Gottlieb, Alan M Mendelsohn, Jeff Parno
Ixekizumab and pregnancy outcomes in patients with psoriasis or psoriatic arthritis
Ixekizumab and pregnancy outcomes in patients with psoriasis or psoriatic arthritis
Alexander Egeberg, Steven R. Feldman, Elisabeth Riedl, Gaia Gallo, Noah Agada
Duration of response - application of adjusted Kaplan Meier curves comparing ixekizumab and ustekinumab
Duration of response - application of adjusted Kaplan Meier curves comparing ixekizumab and ustekinumab
Marc Radtke, Curdin Conrad, Christopher Schuster, Katie Murphy, Antonio Costanzo
Long-term Safety of Tildrakizumab in Patients with Psoriasis: Incidence of Malignancies Through 3 Years from 2 Phase 3 Trials
Long-term Safety of Tildrakizumab in Patients with Psoriasis: Incidence of Malignancies Through 3 Years from 2 Phase 3 Trials
Kristian Reich, Christopher EM Griffiths, Lars Iversen, Andrea Peserico, Ignasi Pau-Charles
Technical Challenges of Applying Artificial Intelligence (AI) on Psoriasis Images for Automated PASI Assessment
Technical Challenges of Applying Artificial Intelligence (AI) on Psoriasis Images for Automated PASI Assessment
Yasmeen George, Jenny Nicolopoulos, Con Dolianitis, Mi Vu, Brent Doolan
Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis-An Analysis from a Phase 2 Study
Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis-An Analysis from a Phase 2 Study
Alice B Gottlieb, Rocco  Ballerini, Richard  C Chou, Stephen J Rozzo, Alan M Mendelsohn
An oral, selective TYK2 inhibitor, deucravacitinib, in patients with moderate-to-severe plaque psoriasis and baseline PASI ≤15 versus >15
An oral, selective TYK2 inhibitor, deucravacitinib, in patients with moderate-to-severe plaque psoriasis and baseline PASI ≤15 versus >15
Peter Foley, Melinda Gooderham, Kenneth Gordon, Diamant ThaçI, Renata Kisa,
Psoriasis Treatment in a Dermatology Day Unit: A Clinical Audit
Psoriasis Treatment in a Dermatology Day Unit: A Clinical Audit
Clare Allison, Shireen Sidhu
Secukinumab improves anxiety and depression in patients with moderate-to-severe psoriasis: results from the SUPREME study
Secukinumab improves anxiety and depression in patients with moderate-to-severe psoriasis: results from the SUPREME study
Juliana Lamoury


No presentations found for today.